Sexuality. The Pharmacologic Treatment of Female Sexual Dysfunction: Future Reality or Wishful Thinking? Risks of Opening the Medicine Cabinet
|
|
- Gloria Stevens
- 5 years ago
- Views:
Transcription
1 5 th Annual Meeting of the North American Menopause Society October 5, 4 Washington, DC Low Libido at Midlife: Will the Answer Ever Be in Our Medicine Cabinets? The Pharmacologic Treatment of Female Sexual Dysfunction: Future Reality or Wishful Thinking? Disclosures New England Research Institutes Research consultant Jan L. Shifren, M. D. Associate Professor of Obstetrics, Gynecology, and Reproductive Biology Harvard Medical School Director, Mass General Midlife Women s Health Center Massachusetts General Hospital Physiology Interpersonal Relationships Sexuality Psychology Sociocultural Influences Risks of Opening the Medicine Cabinet Medicalizing normal changes in sexual desire and response that are associated with aging, life stage, and psychological and social factors Pharmacologic treatment is not indicated, if there is no associated personal distress
2 EROS-Clitoral Therapy Device Efficacy of Sildenafil Citrate in Women with Sexual Arousal Disorder FSD women (9 pre/ postmp) No FSD women ( pre/ postmp) Sensation 9% 58% Lubrication 8% % Ability to achieve orgasm Sexual satisfaction 55% 4% 8% 5% Possible mechanism of action: Clitoral blood flow Double-blind, placebocontrolled trial 78 women with arousal disorder Age: 8 to 7 years No difference in efficacy between sildenafil and placebo Any endpoint at any dose Increase From Baseline (%) 5 4 Satisfaction With Sexual Life Estrogenized Estrogen-deficient (n=4/85) (n=8) 5 (n=8/9) (n=) Sildenafil (mg) Billups KL, et al. J Sex Marital Ther ;7:45 Basson R, et al. J Womens Health Gend Based Med. ;:67 Sildenafil Treatment of Women with Antidepressant-Associated Sexual Dysfunction Bupropion Treatment of HSDD in Premenopausal Women Primary Endpoint: Clinical Global Impression Sildenafil vs. PL:.8 (P.)(difference in change from baseline) Secondary Endpoints: SFQ, ASEX, UNM-SFI Sildenafil group had higher mean improvement vs. PL for all domains, except pain Significant difference in change from baseline for ability to reach orgasm & orgasm satisfaction 98 premenopausal women w/ treated depression New sexual dysfunction after SRI use Sildenafil 5- mg vs. PL prior to sex for 8 weeks Side effects: headache, flushing, dyspepsia Nurnberg HG, et al. JAMA 8;:95-44 Changes in Arousal Scores Randomized, double blind, placebo-controlled study 66 Premenopausal women, non-depressed Bupropion SR -4 mg/d x days Inhibits both dopamine & norepinephrine reuptake Significant CSFQ total score & pleasure, arousal, orgasm subscales Side effects: agitation, HTN, insomnia, dry mouth, tremor, rare seizures Seagraves RT, et al. J Clin Psychopharmacol 4;4:9-4 Changes in Orgasm Scores
3 Low Dose Local Estrogens for Treatment of Vaginal Atrophy & Dyspareunia Ospemifene Effectively Treats Vulvovaginal Atrophy in Postmenopausal Women Vaginal cream: E & CE (.5- gram, - times/week) Vaginal ring (Q months) Vaginal tablet ( times/week) Ospemifene 6 mg significantly decreased most bothersome moderate to severe symptom of vaginal dryness & dyspareunia compared with placebo Bachmann GA, Komi JO, et al. Menopause ;7:48 Score Score 6 4 Testosterone Injections and Sexual Function 5 4 Sexual Desire B 4 Weeks Sexual Arousal B Weeks Coitus/wk B 4 B 4 Weeks Weeks control estradiol estradiol + testosterone injection P<. Sherwin & Gelfand. Psychosom Med 987; 49: 97 Sexual Fantasies Use of a Transdermal Testosterone Patch in Hypoactive Sexual Desire Disorder Phase clinical trials - 4-weeks - Multicenter, double-blind, placebo-controlled 95 surgically & 549 naturally menopausal women on ET or EPT with HSDD Randomized groups - - Testosterone mcg/d Simon JA, et al. J Clin Endocrinol Metab 5; 9:56 Buster J, et al. Obset Gynecol 5; 5:944 Shifren J, et al. Menopause 6; :77
4 Increase in Total Satisfying Sexual Activity Sexuality Domains in Naturally Menopausal Women 4 Wk. Frequency Change From Baseline (SEM) INTIMATE SM p=. INTIMATE SM % increase from baseline % 74% % 5% Simon JA, et al. J Clin Endocrinol Metab 5; 9:56 Buster J, et al. Obset Gynecol 5; 5:944 p=. TTP Mean Change From Baseline (SEM) Desire Arousal Orgasm Pleasure Shifren et al. Menopause; 6; : 77 Decreased Concerns Testosterone Responsiveness Self-image p<.; p<. vs. placebo Combined Estrogen & Testosterone Risk of Breast Cancer in Menopausal Women Participants Person-Years Cases (no.) RR (95% CI) Never Users 557,577,647 Past Users 6, (.8-) Current Users E only 46,8 85. (.-.) E + P.6 (.4-.7) E + T 5, (.-.6) T only 6.5 (.8-7.9) Nurses Health Study - prospective cohort (978-) ( mill person-yrs) st Epidemiologic study to assess androgen HT & breast cancer Significant risk breast cancer in E + P & E + T users Study Limitations Methyltestosterone (Estratest) principal T compound studied 98% E + T users were prior HT users & study did not account for type or duration of prior HT use in T users T users younger, more benign breast disease, more alcohol Testosterone Vaginal Cream The Oprah Winfrey Prescription ( ~/ th male dose) % Testosterone cream Compounded by pharmacist Apply.5 grams topically nightly Dispense 45 grams (~ month supply) NO Data on Safety or Efficacy! Goal: serum testosterone level within normal range for women (FTI = Total T/SHBG x.47; Normal < 4.5) Tamimi et al. Arch Intern Med 6; 66:48 4
5 Testosterone Products in Use for Women Testosterone patch (Intrinsa) approved in Europe for surgically menopausal women w/ HSDD on HT, but no longer being manufactured Off-label use of testosterone products approved for men Effect of Vaginal Testosterone Treatment on Testosterone Levels Testosterone Levels (ng/dl) weeks n= postmenopausal women with vulvar lichen sclerosis Joura EA, et al. Obstet Gynecol 997;89:87 LibiGel Phase III Pivotal Trials: No statistically significant difference in ANY endpoint c/w placebo Safety Data: not released Median Free T (pg/ml) LibiGel mcg/day Intrinsa mcg/day Baseline Month Month Month Month 6 Month of Treatment biosantenews@biosantepharmaceuticals.ccsend.com (.) Testosterone Dose-Response: Postmenopausal Women without Sexual Dysfunction Study Design - 7 Postmenopausal hysterectomized women +/- BSO - Concurrent transdermal estradiol (5 mcg) - vs. IM Testosterone (, 6.5,.5, 5 mg) Q wk x 4weeks Results (c/w placebo) - Supraphysiologic T levels with all doses above mg - Sexual thoughts/desire & frequency sexual activity (BISFW) increased significantly only in women treated with T 5 mg - PGWB composite score & vitality domain increased significantly in women treated with T.5 & 5 mg - Lean body mass (.8 kg), chest press, stair-climb power increased significantly only in women treated with T 5 mg - Increased sexual function in women only with supraphysiologic T Huang et al. Menopause 4; :6 5
6 Effects of DHEA on Sexual Function, Well-Being and Menopausal Symptoms in Postmenopausal Women with Low Libido Effect of Intravaginal DHEA on Sexual Function in Postmenopausal Women PLACEBO DHEA (5 P value mg) Sabbatsberg Sexual NS Self-Rating Scale Satisfying Sexual NS Events (per month) Psychological General NS Well-Being MENQUOL NS Change from Baseline (Mean + SD) Randomized, double blind study x 6 weeks 9 Postmenopausal women with low libido DHEA (5 mg): acne & increased hair growth Panjari M, et al. J Sex Med 9;6: 579 MENQUOL Sexual Domain: () Change in sexual desire, () Vaginal dryness during intercourse, () avoiding intimacy Labrie F, et al. Menopause 9;6:9 Androgen Therapy Potential Risks Hirsutism, Acne Virilization - clitorimegaly, voice changes Liver dysfunction Adverse lipid changes ( HDL) Fluid retention with edema, hypertension, exacerbation of heart disease Psychological changes Potential estrogen risks - VTE s, Breast cancer Virilization of female fetus Androgen Use in Menopausal Women Carefully selected women Physiologic reason for testosterone Alternative etiologies & treatments considered Well informed Risks, benefits, off-label, OTC limitations Goal - Physiologic testosterone levels Monitor Response, side effects, Free T, lipids, LFT s Research Long term safety 6
7 Flibanserin Centrally acting neurotransmitters (Serotonin, Dopamine, Norepinephrine) may modulate sexual excitement and inhibition Flibanserin is a 5-HT A -agonist & 5-HT A - antagonist, with theoretical pro-sexual effects Several large Phase III DBRCTs PRE-menopausal women with hypoactive sexual desire disorder (HSDD) Most common AEs: nausea, dizziness, fatigue, somnolence Borsini F, et. al. CNS Drug Rev. ;8:7 Sexual Function Endpoint Flibanserin Efficacy Results in Premenopausal Women Mean change from baseline (over 4 weeks): Flibanserin ( mg qhs) subtracted change P-value Satisfactory Sexual Events Desire (ediary) NS Distress (FSDS-R) <. Desire (FSFI) <. Flibanserin led to significant increase in number of SSEs c/w PL, but did not demonstrate significant improvement in desire (ediary) (co-primary endpoint) Study 5.7 NDA -56 FDA May, McCoy FSQ Apomorphine in Premenopausal Women with Sexual Desire & Arousal Disorders Baseline Dopamine Agonist, FDA approved for Parkinson s Used off-label for male ED & emergency emetic AEs: nausea, vomiting, dizziness, HA, BP DBRCT x weeks: Apomorphine SL (- mg/day) vs. PL 6 premenopausal women, 47% completed crossover study Caruso, et al. Urology 4; 6:955 Apomorphine P value (Apo vs.pl) Desire..4. <.5 Arousal.4..6 <.5 Orgasm.5..7 <. Enjoyment.7.4 <.5 Satisfied..5 <. Frequency Intercourse.5. <. Bremelanotide Melanocortin agonist - analog of naturally occurring hormone, alpha-msh (melanocyte-stimulating hormone) In Phase B Trial of PRE-menopausal women with FSD, bremelanotide (.5 mg &.75 mg SC) significantly increased sexual arousal, desire & number of sexually satisfying events, & decreased associated distress Effective in both women with hypoactive sexual desire disorder (HSDD) and combined HSDD/female sexual arousal disorder (HSDD/FSAD) Most common AEs: facial flushing, nausea, vomiting Elevated BP seen with nasal formulation not seen with SC formulation 7
8 Lybrido/Lybridos Avlimil Treatment of Female Sexual Dysfunction (proprietary herbal formulation) Combination therapy designed to target specific causes of HSDD Lybrido: Sublingual testosterone surrounded by sildenafil for women with HSDD and low arousal Lybridos: Sublingual testosterone surrounded by 5 HT A - agonist (Buspirone) for women with HSDD and sexual inhibition Taken ~ -6 hours prior to planned sexual activity to increase sexual motivation/libido Phase b studies ongoing in US Van Rooij K, et al. J Sex Med ;:79 & 8 & 84; Level of Desire Sage, kudzu root, red clover, capsicum pepper, licorice, bayberry fruit, valerian root, ginger root, black cohosh Randomized, double blind, placebo-based study 65 Women x months (NEARLY) identical to active product Executive Summary on product website Satisfaction with Sexual Life 8
Psykiatri PCK/Sexologisk Klinik Medication for Female Sexual Dysfunction - where are we?
Medication for Female Sexual Dysfunction - where are we? Annamaria Giraldi, Professor, MD, PHD Sexological Clinic Copenhagen, Denmark Disclosures Eli Lilly - lecturer Boehringer advisory board Pfizer -
More informationAn Evidence-based Review of Clinical Trial Data
An Evidence-based Review of Clinical Trial Data Karen K. Miller, MD Massachusetts General Hospital Harvard Medical School Boston, MA 1 Rationale for Investigating Androgen Administration in Women: Data
More informationUnderstanding the Spectrum of Female Sexual Dysfunction
. Understanding the Spectrum of Female Sexual Dysfunction Bruce Kessel, MD Chair Jeanne Leventhal Alexander, MD; Sheila Bolour, MD; Mark Elliott, PhD; Lori Futterman, RN, PhD; Jannet Huang, MD; Lee Shulman,
More informationErin E. Stevens, MD Chair, Department of Gynecologic Oncology Billings Clinic Cancer Center January 18, 2017
Erin E. Stevens, MD Chair, Department of Gynecologic Oncology Billings Clinic Cancer Center January 18, 2017 Objectives Define what's normal Define female sexual dysfunction Identify the causes of female
More informationSexual dysfunction: Is it all about hormones?
Sexual dysfunction: Is it all about hormones? Angelica Lindén Hirschberg, MD, PhD, Professor Department of Women s and Children s Health, Karolinska Institutet and Karolinska University Hospital, Stockholm,
More informationLow sexual desire: Appropriate use of testosterone in menopausal women
Low sexual desire: Appropriate use of testosterone in menopausal women Low-dose testosterone treatment may be considered for HSDD in carefully selected menopausal women after standard therapies have been
More informationTherapy and Sexual Health
Menopausal hormone therapy and sexual health Earn 3 CPD Points online Menopausal Hormone Therapy and Sexual Health Key messages Dr Tobie De Villiers Consultant Gynaecologist Panorama MediClinic Department
More informationAddyi (flibanserin) When Policy Topic is covered Coverage of Addyi is recommended in those who meet the following criteria:
Addyi (flibanserin) Policy Number: 5.01.605 Last Review: 10/2018 Origination: 10/2015 Next Review: 10/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Addyi when
More informationFemale sexual dysfunction
Drug therapy applied to sexuality Impact of POP surgery on female sexuality G. Willy Davila, MD Department of Gynecology Urogynecology/Reconstructive Pelvic Surgery Cleveland Clinic Florida Weston/Ft.
More informationManagement of Menopausal Symptoms
Management of Menopausal Symptoms Tammie Koehler DO, FACOG 1 Menopause Permanent cessation of menstruation that occurs after the loss of ovarian activity Determined to have occurred after 1 full year of
More informationHypoactive Sexual Desire Disorder: Advances in Diagnosis and Treatment
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More information10/24/2014. Definitions and Epidemiology Physiology of Female Sexual Response Female Sexual Dysfunction
None to report Tami Serene Rowen, M.D. M.S. Department of Obstetrics, Gynecology and Reproductive Sciences University of California, San Francisco October 24, 2014 Definitions and Epidemiology Physiology
More informationOutline. Do Women Care about Sex? 3/22/2016. Aging and sexuality: More than just menopause. Sexual Health is. Definitions and Epidemiology
Outline Definitions and Epidemiology Aging and sexuality: More than just menopause Physiology, Definitions, Dysfunction Tami Rowen MD MS Assistant Professor UCSF Department of ObGyn&RS Physiology of Female
More informationSexual dysfunction in women with cancer: Navigating intimacy and intercourse between women and their partners
Sexual dysfunction in women with cancer: Navigating intimacy and intercourse between women and their partners Don S. Dizon, MD, FACP Clinical Co-Director, Gynecologic Oncology Founder and Director, The
More information9/30/2016. Data and Women s Preferences Should Inform the Treatment of Hypoactive Sexual Desire Disorder: The Case for Pharmacologic Agents
Data and Women s Preferences Should Inform the Treatment of Hypoactive Sexual Desire Disorder: The Case for Pharmacologic Agents Sources of Evidence for Physiological Mechanisms Modulating Sexual Desire
More informationDesire for Desire. Michael L Krychman MD
Desire for Desire Michael L Krychman MD Executive Director of the Southern California Center for Sexual Health and Survivorship Medicine AASECT Certified Sexual Counselor Associate Clinical Professor UCI
More informationOBSTETRICS & GYNECOLOGY
JANUARY 2012 COMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING WWW.CPSRXS. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Female Sexual Arousal
More informationOutline. Clinic Visit: Mrs. Jones 3/10/2015
Outline Kim O Connor, MD, FACP Associate Professor University of Washington General Internal Medicine Sexual Response Cycle Categories of Female Sexual Dysfunction Biopsychosocial influences History Evaluation
More informationFEMALE SEXUAL DYSFUNCTION-DRUG THERAPY. Dr. Renee Horowitz M.D FACOG Woman s Urology Center Beaumont Hospital
FEMALE SEXUAL DYSFUNCTION-DRUG THERAPY Dr. Renee Horowitz M.D FACOG Woman s Urology Center Beaumont Hospital CONFLICT OF INTEREST SPEAKER: AMAG PHARMACEUTICALS LUMENIS DEFINITIONS DSM-IV VS DSM-V DSM IV
More informationSex Cells The effect of hormones on peri- and post- menopausal female sexuality Dr. Cathy Caron November 24, 2011
Sex Cells The effect of hormones on peri- and post- menopausal female sexuality Dr. Cathy Caron November 24, 2011 Is sex over at menopause? Older adults are having sex 51% of women ages 50 to 59 report
More informationI have no disclosures to report. Addressing Female Sexual Needs. Sexual health. Objectives. WHO definition of sexual health:
Addressing Female Sexual Needs I have no disclosures to report Essentials of Women s Health Conference Big Island, Hawaii July 2016 Jennifer Kerns, MD, MS, MPH Assistant Professor, UCSF Department of Obstetrics,
More informationFlibanserin for Hypoactive Sexual Desire Disorder: Can We Bring Back that Loving Feeling?
Flibanserin for Hypoactive Sexual Desire Disorder: Can We Bring Back that Loving Feeling? Lori D. Watkins, Pharm.D PGY1 Pharmacy Practice Resident Methodist Hospital, San Antonio, Texas Division of Pharmacotherapy,
More informationWomen s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School
Women s Health: Managing Menopause Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School Disclosures I have no conflicts of interest. Learning Objectives 1. Apply strategies to help
More informationREVIEW Testosterone therapy in women: its role in the management of hypoactive sexual desire disorder
(2007) 19, 458 463 & 2007 Nature Publishing Group All rights reserved 0955-9930/07 $30.00 www.nature.com/ijir REVIEW : its role in the management of hypoactive sexual desire disorder Department of Obsterics
More informationLeslie R. Schover, PhD Department of Behavioral Science
Causes and Treatments of Low Sexual Desire in Breast Cancer Survivors Leslie R. Schover, PhD Department of Behavioral Science IMPORTANCE OF SEX TO BREAST CANCER SURVIVORS Livestrong 2006 Post-Treatment
More informationMayo Clin Proc, July 2002, Vol 77 Female Sexual Dysfunction Sexual pain disorder: the persistent or recurrent genital pain associated with non
698 Concise Review for Clinicians Female Sexual Dysfunction DEBORAH J. LIGHTNER, MD Female sexual dysfunction (FSD) was recently recognized as arising from multiple organic etiologies; it is not primarily
More informationFemale Sexuality Sheryl A. Kingsberg, Ph.D.
Female Sexuality Sheryl A. Kingsberg, Ph.D. Professor of Reproductive Biology Case Western Reserve University School of Medicine Chief, Division of Behavioral Medicine Department of OB/GYN University Hospitals
More informationSexuality and Sexual Dysfunction in Women
Sexuality and Sexual Dysfunction in Women Denise M.S. Willers, MD Associate Professor of Obstetrics and Gynecology Washington University School of Medicine Disclosures No financial disclosures to make
More informationHypoactive Sexual Desire Disorder (HSDD)
Hypoactive Sexual Desire Disorder (HSDD) Sharon J. Parish, MD Professor of Medicine in Clinical Psychiatry; Professor of Clinical Medicine 10/07/17 shp9079@med.cornell.edu 1 Conflict Of Interest Disclosure
More informationMENOPAUSAL HORMONE THERAPY 2016
MENOPAUSAL HORMONE THERAPY 2016 Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA NICE provides the National Health Service advice on effective, good value healthcare.
More informationTestosterone therapy for sexual dysfunction in postmenopausal women
CLIMACTERIC 2008;11:181 191 Testosterone therapy for sexual dysfunction in postmenopausal women Z. Hubayter* and J. A. Simon { *Division of Reproductive Endocrinology and Infertility, Department of Gynecology
More informationAssessment of female sexual dysfunction: review of validated methods
FERTILITY AND STERILITY VOL. 77, NO. 4, SUPPL 4, APRIL 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Assessment
More informationManagement of Menopausal Symptoms in Patients with Breast Cancer. Mike Dixon Edinburgh Breast Unit
Management of Menopausal Symptoms in Patients with Breast Cancer Mike Dixon Edinburgh Breast Unit Menopausal symptoms have a major impact on Quality of Life Variety of Symptoms associated with the Menopause
More informationCarmita Abdo, MD PhD. Medical School, University of São Paulo Program of Studies in Sexuality (ProSex)
Carmita Abdo, MD PhD Medical School, University of São Paulo Program of Studies in Sexuality (ProSex) Carmita Abdo, MD PhD As per Rule 1595/2000 of the Federal Medical Council and Resolution RDC 102/2000
More informationLearning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories
Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen
More informationSexuality After the Diagnosis of Ovarian Cancer
Sexuality After the Diagnosis of Ovarian Cancer June La Valleur, MD, FACOG, Sexual Health Counselor Associate Professor, Ret., University of Minnesota Medical School Sexual Health Consultant at Skyhill
More informationThe Clinical Effect of Androgen Replacement Therapy for Female Sexual Dysfunction
Original Article Ewha Med J 2011;34(2):33-38 pissn 2234-3180 / eissn 2234-2591 The Clinical Effect of Androgen Replacement Therapy for Female Sexual Dysfunction Seong Ju Lee, Woo Sik Chung, Hana Yoon Department
More informationMENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE?
MENOPAUSE WHAT S NEW? WHAT S SAFE? I have no disclosures Sara Whetstone, MD, MHS OBJECTIVES To describe risks of HT by age and menopause onset To recommend specific HT regimen for women who undergo early
More informationSexual problems- some basic information
Sexual Problems 1 Soheil A. Hanjani, MD, FACOG, FACS Obstetrics & Gynecology 830 Oak Street Brockton, MA 02301 (508) 583-4961 Fax (508) 583-4732 Soheil.Hanjani@Steward.org www.hanjanimd.com Sexual problems-
More informationSexual dysfunction of chronic kidney disease. Razieh salehian.md psychiatrist
Sexual dysfunction of chronic kidney disease Razieh salehian.md psychiatrist Disturbances in sexual function are a common feature of chronic renal failure. Sexual dysfunction is inversely associated with
More informationFlibanserin for Treating Hypoactive Sexual Desire Disorder
pissn: 2288-6478, eissn: 2288-6761 Review Article Flibanserin for Treating Hypoactive Sexual Desire Disorder Jae Hong Sang 1, Tae-Hee Kim 2, Soo Ah Kim 3 1 Department of Obstetrics and Gynecology, Soonchunhyang
More informationSexual difficulties in the menopause
Sexual difficulties in the menopause Information Sheet Key points Sexual difficulties can be life-long or recently acquired, but they are a common presentation at menopause. Hormones are rarely the only
More informationNew Treatments for Vaginal Health. Sarah Azad, MD El Camino Women s Medical Group
New Treatments for Vaginal Health There s Hope Sarah Azad, MD El Camino Women s Medical Group The Genitrourinary Syndrome of Menopause (GSM) Problems with genital health secondary to the changes that occur
More informationDr. Maliheh Keshvari
1 Dr. Maliheh Keshvari Assistant professor of Urology Fellowship in Female Urology Mashhad University of Medical Sciences 2 Female Sexual Function and Dysfunction 3 It was not until recently that urologists
More informationPractically overnight, the Women s
OBG BY LOUANN BRIZENDINE, MD MANAGEMENT Managing menopause-related depression and low libido Anne is distressed by hot flashes, depressive symptoms, and loss of sexual drive, and her marriage is suffering
More informationWHI Estrogen--Progestin vs. Placebo (Women with intact uterus)
HORMONE REPLACEMENT THERAPY In the historical period it was commonly held that estrogen had two principal benefits to postmenopausal women: 1) To alleviate the constitutional symptoms related to the climacteric
More informationMenopausal Management: What Has Changed?
Menopausal Management: What Has Changed? Julia V. Johnson, M.D. Professor and Chair, OB/GYN University of Massachusetts Medical School UMass Memorial Medical Center Conflicts of Interest None Learning
More informationMenopause and Post Gynecological Reproductive Care
Menopause and Post Gynecological Reproductive Care Nguyet-Cam Vu Lam, MD, FAAFP Associate Program Director St. Luke s Family Medicine Residency 1 Disclosure Dr. Nguyet-Cam Vu Lam has no conflict of interest,
More informationNivedita Dhar M.D. Wayne State University April 25, 2013
Female Sexual Dysfunction Nivedita Dhar M.D. Wayne State University April 25, 2013 Outline Define Sexual Health and Wellness and discuss how it is unique to each individual Discuss the current terminology
More informationOBSTETRICS & GYNECOLOGY
AUGUST 2011 NORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING N ORLANDA VENUEP HARMACY. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: BHRT for Menopause
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Safety and Efficacy of a Testosterone Patch for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women A Randomized, Placebo-Controlled Trial Glenn D.
More informationSexual Health: What s New in 2016
Sexual Health: What s New in 2016 Financial Disclosures Husband full time employee Genomic Health No material in this presentation relates to this company Tami Serene Rowen Assistant Professor UCSF Department
More informationPrior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD
Prior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD JoAnn V. Pinkerton, MD Professor of Obstetrics and Gynecology Director,
More informationFemale Sexual Dysfunction: Clinical approach
Female Sexual Dysfunction: Clinical approach - What Nurses want to know - Alessandra Graziottin MD Director, Center of Gynecology and Medical Sexology H.San Raffaele Resnati, Milano, Italy Co-Director,
More informationMenopause Matters. Equity Office Staff Seminar 14 November 2018
Menopause Matters Equity Office Staff Seminar 14 November 2018 1 What to expect at menopause How to manage symptoms Support at work Dr Janice Brown Medical lead, The University of Auckland NZ representative,
More informationScream Cream. Ingredients: Aminophylline 15-mg, Ergoloid mesylate 0.25-mg, Pentoxifylline 25-mg and L-Arginine 30-mg
At LifeCare Pharmacy we understand that women have different needs at different stages of their lives. Maintaining a healthy and balanced lifestyle can be a difficult struggle. The chronic stress of overly
More informationProcess of Aging. Manifestation of Estrogen and/or Androgen Loss: Symptoms Over Time. Estrogen Decrease and Its Impact on Sexual Functioning
Impact of Vulvovaginal Atrophy on Quality of Life and Sexuality Process of Aging physical health sexual activity Sexual function and aging desire androgen levels Michael L. Krychman MD Executive Director
More informationDisease (diabetic neuropathy, multiple sclerosis, tumors, and, rarely, tertiary syphilis)
COURSES ARTICLE - THERAPYTOOLS.US Individual Planning: A Treatment Plan Overview for Adult Men with Sexual Performance Problems Individual Planning: A Treatment Plan Overview for Adult Men with Sexual
More informationAVAILABLE FOR PUBLIC DISCLOSURE WITHOUT REDACTION
ABCD Briefing Document Doc. Id.: US Drug Substance: Dosage Form, Strength: Indication: Flibanserin (BIMT 17 BS) Film-coated tablets 100 mg Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women
More informationThe New England Journal of Medicine TRANSDERMAL TESTOSTERONE TREATMENT IN WOMEN WITH IMPAIRED SEXUAL FUNCTION AFTER OOPHORECTOMY
TRANSDERMAL TREATMENT IN WOMEN WITH IMPAIRED SEXUAL FUNCTION AFTER OOPHORECTOMY JAN L. SHIFREN, M.D., GLENN D. BRAUNSTEIN, M.D., JAMES A. SIMON, M.D., PETER R. CASSON, M.D., JOHN E. BUSTER, M.D., GEOFFREY
More informationResilient Intimacy. Richa Sood, M.D.
Resilient Intimacy Richa Sood, M.D. Disclosures No financial conflicts My specialty is Female Sexual Dysfunction Common Questions What is normal sexuality, and how does it change with medical illness?
More informationPHARMACOTHERAPY OF SMOKING CESSATION
PHARMACOTHERAPY OF SMOKING CESSATION Domenic A. Ciraulo, MD Director of Alcohol Pharmacotherapy Research Center for Addiction Medicine Department of Psychiatry Massachusetts General Hospital Disclosure
More informationDisclosures. Learning Objectives. Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease. None
Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease Micol S. Rothman, MD Associate Professor of Medicine Endocrinology, Diabetes and Metabolism Clinical Director Metabolic Bone
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationSexual Health and Dysfunction in the Elderly. Nadya S. Dávila Lourido, MD September 28, 2018
Sexual Health and Dysfunction in the Elderly Nadya S. Dávila Lourido, MD September 28, 2018 Objectives: To review physiologic changes associated with aging To discuss the importance of the history and
More informationEvaluation of Systemic Effects of a Vaginal Estradiol Softgel Capsule Insert (TX-004HR) in Menopausal Women with Moderate to Severe Dyspareunia
Evaluation of Systemic Effects of a Vaginal Estradiol Softgel Capsule Insert (TX-4HR) in Menopausal Women with Moderate to Severe Dyspareunia Lisa Larkin, MD 1 ; Andrew M Kaunitz, MD 2 ; James Liu, MD
More informationFEMALE AROUSAL AND ORGASMIC COMPLAINTS IN A DIVERSE CANCER POPULATION TREATED WITH ZESTRA: A TOPICAL APPLIED BLEND OF BOTANICAL OILS
FEMALE AROUSAL AND ORGASMIC COMPLAINTS IN A DIVERSE CANCER POPULATION TREATED WITH ZESTRA: A TOPICAL APPLIED BLEND OF BOTANICAL OILS Michael L Krychman MD Executive Director of the Southern California
More informationThe menopause is considerably more than just. Hormonal Changes in Menopause and Implications on Sexual Health
220 Hormonal Changes in Menopause and Implications on Sexual Health Anneliese Schwenkhagen, MD Gynaekologicum Hamburg, Hamburg, Germany DOI: 10.1111/j.1743-6109.2007.00448.x ABSTRACT Introduction. The
More informationAndrogens: Putting Sex Drive Back into Gear? Loss of sexual desire occurs more frequently. In this article: Joanne s lack of desire
Focus on CME at Queen s University Focus on CME at McMaster University Androgens: Putting Sex Drive Back into Gear? By John A. Lamont, MD, MSc, FRCSC Joanne s lack of desire Joanne, 37, is married and,
More informationACTIVITY DISCLAIMER DISCLOSURE. Associated Session(s) Learning Objectives. Female Sexual Dysfunction: Demystifying the Secret Garden
ACTIVITY DISCLAIMER Female Sexual Dysfunction: Demystifying the Secret Garden Phyllis MacGilvray, MD, FAAFP The material presented here is being made available by the American Academy of Family Physicians
More informationInnovations in the Management of Dyspareunia
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationSEXUAL PAIN Home messages, a summary from Presentations, moderated Posters and Podiums
SEXUAL PAIN Home messages, a summary from Presentations, moderated Posters and Podiums María Luisa Banfi, MD Gynecologist, Sexologist Montevideo, Uruguay, South America CHICAGO 2012,SMS- ISSM, World Meeting
More informationSexual disorders such as premature ejaculation,
For mass reproduction, content licensing and permissions contact Dowden Health Media. Restoring sexual function: Which medications show benefit? When trying centrally acting or topical agents, also address
More informationMenopause and HRT. John Smiddy and Alistair Ledsam
Menopause and HRT John Smiddy and Alistair Ledsam Menopause The cessation of menstruation Diagnosed retrospectively after 1 year of amenorrhoea Average age 51 in the UK Normal physiology - Menstruation
More informationVVA : new therapeutic options? BMS october 2017 A Pintiaux
VVA : new therapeutic options? BMS october 2017 A Pintiaux Disclosures Member of the european board of TEVA without personal gain No conflict of interest for this presentation VVA Vulvar and vaginal atrophy
More informationSouthern California Center for Sexual Health and Survivorship Medicine Inc, Newport Beach, CA 3
The WISDOM survey: Physicians Level of Comfort Prescribing Treatment for Vulvar and Vaginal Atrophy (VVA) Symptoms in Women with a Predisposition or History of Breast Cancer Lisa Larkin, MD 1 ; Michael
More informationNavigating the Change: Leading Patients Through Menopause
4:30pm - 5:30pm: Breakout 5 - Women s Health Option A: Navigating the Change: Leading Patients Through Menopause ACPE UAN 0107-0000-10-025-L01-P 0.1 CEU/1.0 Hr. Activity Type: Application-Based Program
More informationSex & Intimacy when Living with Cancer
Sex & Intimacy when Living with Cancer Jeffrey Albaugh, PhD, APRN, CUCNS NorthShore University Healthcare William D. & Pamela Hutel Ross Sexual Health Clinic Jalbaugh@northshore.org Sexual Dysfunction
More informationSexual Devices: Clitoral Stimulator, Dilators and Vibrators
Sexual Devices: Clitoral Stimulator, Dilators and Vibrators Michael L. Krychman MD Associate Clinical Attending UCI Irvine, CA Executive Director Southern California Center for Sexual Health and Survivorship
More informationDisclosures. Triptans for Kids 5/16/13
5/16/13 Disclosures Triptans for Kids Amy A. Gelfand, MD GelfandA@neuropeds.ucsf.edu Departments of Neurology and Pediatrics UCSF Child Neurology and Headache Center I receive grant funding from: NIH/NINDS
More information25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy?
Research Subcutaneous estrogen replacement therapy. Jones SC. Journal of Reproductive Medicine March, 2004; 49(3):139-142. Department of Obstetrics and Gynecology, Keesler Medical Center, Keesler Air Force
More informationInterventions to Address Sexual Problems in People with Cancer
A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Interventions to Address Sexual Problems in People with Cancer L. Barbera, C. Zwaal, D. Elterman, K. McPherson,
More informationManagement of SSRI Induced Sexual Dysfunction. Serotonin Reuptake Inhibitors*
Management of SSRI Induced Sexual Dysfunction John J. Miller, M.D. Medical Director, Center for Health and WellBeing Exeter, NH Serotonin Reuptake Inhibitors* fluoxetine clomipramine sertraline paroxetine
More informationAre changes in sexual functioning during midlife due to aging or menopause?
FERTILITY AND STERILITY VOL. 76, NO. 3, SEPTEMBER 2001 Copyright 2001 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Are changes in sexual
More informationCoincident with the advent of effective oral therapy for erectile. Managing hypoactive sexual desire in women. CME Feature
CME Feature Managing hypoactive sexual desire in women Anthony J. Viera, MD ABSTRACT Decreased sexual desire afflicts one third of adult women in this country. Difficulty in diagnosing this condition is
More informationCONTRACEPTION DISCLOSURES OBJECTIVES ACKNOWLEDGEMENTS AND SEXUAL FUNCTION 10/21/2014
CONTRACEPTION AND SEXUAL FUNCTION Susan Kellogg Spadt, PhD, CRNP,IF,FCST Director: Female Sexual Medicine Academic Urology Center for Pelvic Medicine Bryn Mawr Pa Prof. OBGYN: Drexel University College
More informationA Practitioner s Toolkit for the Management of the Menopause
Medicine, Nursing and Health Sciences A Practitioner s Toolkit for the Management of the Menopause Developed by the Women s Health Research Program School of Public Health and Preventive Medicine Monash
More informationUpdating the Female Nomenclature: ICSM, ISSWSH, and ICD-11 Classification. Sharon J. Parish, MD, IF, NCMP 2017 Annual Scientific Program May 12, 2017
Updating the Female Nomenclature: ICSM, ISSWSH, and ICD-11 Classification Sharon J. Parish, MD, IF, NCMP 2017 Annual Scientific Program May 12, 2017 Disclosures Advisory Board Palatin, Valeant Speaker
More informationApproximately 40% of women will experience. Female Sexual Dysfunction Focus on Low Desire. Clinical Expert Series
Clinical Expert Series Female Sexual Dysfunction Focus on Low Desire Sheryl A. Kingsberg, PhD, and Terri Woodard, MD Low or absent sexual desire is the most common sexual dysfunction in women, and its
More informationSEXUALITY AND INTIMACY AFTER CANCER
SEXUALITY AND INTIMACY AFTER CANCER Don S. Dizon, MD Head of Women s Cancers, Lifespan Cancer Institute Director of Medical Oncology, Rhode Island Hospital Associate Professor of Medicine, Warren Alpert
More informationWOMEN S HEALTH: A REVIEW OF THIS YEAR S MOST IMPORTANT PAPERS OVERVIEW BUT NOT. TOPICS 8/14/2009. Judith Walsh, MD, MPH Professor of Medicine UCSF
WOMEN S HEALTH: A REVIEW OF THIS YEAR S MOST IMPORTANT PAPERS Judith Walsh, MD, MPH Professor of Medicine UCSF OVERVIEW Update in Women s Health for SGIM Drs. Mary Beattie and Pam Charney Review of literature
More informationSexuality and Bone Marrow Failure Diseases: A Conversation
Sexuality and Bone Marrow Failure Diseases: A Conversation Timothy Pearman, Ph.D. Director, Supportive Oncology Associate Professor Dept. of Medical Social Sciences Dept. of Psychiatry and Behavioral Sciences
More informationPharmacologic treatment options for hypoactive sexual desire disorder
REVIEW Pharmacologic treatment options for hypoactive sexual desire disorder Sheila Y Bolour 1 & Glenn D Braunstein 2 Author for correspondence 1 Cedars-Sinai Medical Center, David Geffen School of Medicine,
More informationYear: Issue 1 Obs/Gyne The silent epidemic: Postmenopausal vaginal atrophy
Year: 2013 - Issue 1 Obs/Gyne The silent epidemic: Postmenopausal vaginal atrophy By: Dr David W Sturdee, Immediate past President International Menopause Society and Hon Consultant Gynaecologist, Solihull
More informationFlibanserin and Female Sexual Desire
Rx Photo Pixland / thinkstockphotos.com E Editor s note: The Rx column is intended to objectively inform and report on new developments in pharmacologic treatments and medical devices. Because in many
More informationTreating GSM without Estrogens. Lubrication and Vaginal Dilators
Treating GSM without Estrogens Lubrication and Vaginal Dilators Hope K. Haefner, MD Michigan Medicine Ann Arbor, MI USA Disclosures/Conflicts of Interest Hope Haefner, MD has no disclosures or conflicts
More information85% 98% 6/12/2018. Disclosures. There is a need. There is a need and that need is unmet. Objectives. Barriers to meeting sexual health needs
Disclosures No financial disclosures Addressing the Sexual Health Needs of Cancer Survivors: Applying Theory and Research to Practice Kristen M. Carpenter, Ph.D. June 11, 2018 There is a need There is
More informationManaging menopause in Primary Care and recent advances in HRT
Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG PG Cert. Advanced Gynaecology Endoscopy Consultant Gynaecologist Heart of England NHS Foundation Trust Spire Parkway
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: This drug is not marketed in the United States.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationattitudes toward sexuality. Further, early sexual experiences and relationships, whether positive or negative, define our sexuality in adulthood. FEMA
CONCISE UNDERSTANDING REVIEW WOMEN S SEXUAL FOR HEALTH CLINICIANS Understanding Women s Sexual Health: A Case-Based Approach MARY L. MARNACH, MD, AND PETRA M. CASEY, MD On completion of this article, you
More information